Session » T cell Biology and Targets in Autoimmune Disease Poster I

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1940

A Circulating Reservoir of Pathogenic-like CD4+ T Cells Shares a Genetic and Phenotypic Signature with the Inflamed Synovial Micro-Environment

9:00AM-11:00AM: Abstract Number: 1946

A Novel HLA-DRB1*10:01 Restricted T Cell Epitope from Citrullinated Type II Collagen Relevant for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1939

Anti-GM-CSF Treatment Promotes Synovial Monocyte-Derived Dendritic Cells and Increases Th17 Cells during Experimental Arthritis

9:00AM-11:00AM: Abstract Number: 1934

Autophagy Pathway As a Target of Therapeutic P140 Peptide Used in Lupus

9:00AM-11:00AM: Abstract Number: 1942

B Cell Depletion By Rituximab in Lymphocyte Subpopulations from Peripheral Blood in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1937

Dalazatide (ShK-186), a First-in-Class Blocker of Kv1.3 Potassium Channel on Effector Memory T Cells: Safety, Tolerability and Proof of Concept of Immunomodulation in Patients with Active Plaque Psoriasis

9:00AM-11:00AM: Abstract Number: 1944

Dalazatide Modulates CD4+ Effector Memory T-Cell Activity of Patients with Granulomatosis with Polyangiitis in Vitro

9:00AM-11:00AM: Abstract Number: 1948

Early Rheumatoid Arthritis Patients Have Higher Fractions of Circulating Th2 Cells, Th17 Cells and Regulatory T Cells, Similar Fractions of Follicular Helper T Cells, and Lower Fractions of Th17/Th1 Cells and Th1 Cells Compared to Healthy Controls

9:00AM-11:00AM: Abstract Number: 1938

Engaging PD-1 Resuscitates Synovial Treg Cells and Dampens the Joint Infiltrating T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1949

Generation and Immunophenotyping of Citrullin-Specific T Cell Lines from Peripheral Blood and Synovial Fluid of ACPA+ RA Patients

9:00AM-11:00AM: Abstract Number: 1947

Hypermethylation of Treg-Specific Demethylated Regions in the Ikaros Transcription Factor Family Members, Helios and Eos, in Rheumatoid Arthritis Tregs

9:00AM-11:00AM: Abstract Number: 1930

Identification of a Broadly Immunogenic Prevotella Copri T Cell Epitope in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1932

IL-17A-Low CCR6+ Th Cell Populations of Patients with Rheumatoid Arthritis Are Pathogenic, Multidrug Resistant and Associated with DMARD and Glucocorticoid Treatment Response

9:00AM-11:00AM: Abstract Number: 1950

Methylation-Dependent Interference of Two Promoters for the Treg-Specific Protein, Garp, Contributes to Altered Treg Function in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1945

microRNA-30a Promotes the Inflammatory Response of Rheumatoid Arthritis By Regulating Th1 Cell Differentiation

9:00AM-11:00AM: Abstract Number: 1931

PLCe1 Mediates Cellular Adhesion Downstream of SDF-1 in T Cells

9:00AM-11:00AM: Abstract Number: 1943

Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-Type Hypersensitivity and Psoriasis

9:00AM-11:00AM: Abstract Number: 1935

Regulation of T Follicular Helper Cells in Systemic Lupus Erythematosus By E3 Ubiquitin Ligase Cbl-b

9:00AM-11:00AM: Abstract Number: 1933

Rheumatoid Arthritis Patient T Cells Recognize Neutrophil Extracellular Traps

9:00AM-11:00AM: Abstract Number: 1941

Senescent T-Cells Expedite RANKL-Dependent Bone Loss in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1929

Somatic Mutations in Clonally Expanded Cytotoxic Lymphocytes in Patients with Newly Diagnosed Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1936

STAT3-Regulated Gene Expression in Circulating CD4+ T Cells Discriminates RA Patients Independently of Clinical Parameters in Early Arthritis: A Validation Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].